The global recombinant DNA technology market size was estimated to be US$ 390 billion in 2020 and is expected to reach US$ 830 billion by 2031 at a CAGR of 7.2%. The appearance of recombinant DNA technology has reformed improvement in science and offered new possibilities for developments. Otherwise, called genetic engineering, it is right now broadly used to modify hereditary material outside an organism and acquire improved and wanted qualities in living beings.
It incorporates the inclusion of DNA pieces from a few sources that have a beneficial quality succession through a proper vector. Other than this, it aids the protected, moderate, and adequate creation of imperative proteins needed for dietary purposes and battling medical conditions.
The market for recombinant DNA technology is being driven by rising innovative work activities to fix or ease illnesses like malignant growth and other immunodeficiency diseases. An improvement in genetically designed human insulin to treat diabetes and the achievement pace of the treatment has set off the development of a few different drugs, which is likewise fuelling the market development in coming years.
Besides, the use of recombinant DNA technology to create genetically changed outputs that are rich in quality is additionally giving further impulse to the market development during 2021-2031. The utilization of recombinant DNA technology in agrarian exercises has prompted cost-effective creation, hence, adding to the market development.
Notwithstanding its rising reception in downstream areas, the technology contrarily affects the climate or human wellbeing, further prodding the market development of recombinant DNA technology.
Some significant factors associated with marketplace are
Clinical rDNA items were seen dominating the market share in 2019 as far as income is considered. This can be credited to the business accomplishment of insulin, which has incited firms for additional advancement of recombinant drugs. Attributable to productive transient and stable articulation abilities, mammalian articulation framework caught the biggest share. This share is likewise upheld by the enhancements in media for high return utilizing a mammalian articulation framework. Wellbeing and illness accounted with the biggest share as far as income is concerned. Quality treatment, antibodies creation, drug digestion examination, recombinant helpful and immunization advancement are perceived as significant uses of this technology in human medical care domain.
In 2020, one of the main organizations in recombinant DNA technology, Sanofi worked together with GSK to create an adjuvanted Coronavirus immunization utilizing inventive and cutting edge innovations. Sanofi utilized its S-protein Coronavirus antigen based on recombinant DNA technology. The technology has created a definite match to the proteins found in the infection, and further procedures will occur with the assistance of the baculovirus articulation stage. Sanofi's drive to foster an antibody against Covid is a significant forward leap for the organization and is relied upon to impel the general development of the business in the coming years. The improvement of recombinant-based Coronavirus immunization by Sanofi is being upheld by Biomedical Advanced Research and Development Authority (BARDA). Such government help as financial aids is relied upon to additional guide the market development of recombinant DNA technology during 2021-2031 forecast time frame.
The biggest share of the North America province can be ascribed to the way that a considerable number of biopharmaceutical producing members are settled in the U.S. Additionally, the presence of powerful administrative bodies to screen the different moral and logical concerns relating to the utilization of technology have driven the territorial development. In July 2017, this nation saw the first FDA endorsement for U.S. quality treatment. The treatment was created for leukemia, because of cooperation between the College of Pennsylvania and Novartis Corp. This, thus, is expected to support the execution of rDNA strategies in the province during 2021-2031.
Global Recombinant DNA Technology Market Value Share Analysis, by Geography (2021)
The report titled “Global Recombinant DNA Technology Market - Global Market Share, Trends, Analysis and Forecasts, 2022-2032”, wherein 2020 is historic period, 2021 is the base year, and 2022 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the Global Recombinant DNA Technology Market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.
The global Recombinant DNA Technology market is segmented as product, component, application, and end use, and region. Based on product, the Recombinant DNA Technology market is segmented into Medical (Therapeutic Agent, Human Protein, Vaccine), Non-medical (Biotech Crops, Specialty Chemicals, Others). Based on component, the Recombinant DNA Technology market is segmented into Expression System (Mammalian, Bacteria, Yeast, Baculovirus/insect, others), Cloning Vector. Based on application, the Recombinant DNA Technology market is segmented into Food & Agriculture, Health & Disease (Human, Animal, Environment), Others. Based on end use, the Recombinant DNA Technology market is segmented into Biotechnology and Pharmaceutical Companies, Academic & Government Research Institutes, Others.
Based on geography, the Global Recombinant DNA Technology Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on Global Recombinant DNA Technology Market. Further, market share of prominent companies in the Global Recombinant DNA Technology Market would also be estimated.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the Recombinant DNA Technology companies. The Global Recombinant DNA Technology Market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the Recombinant DNA Technology business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the Global Recombinant DNA Technology Market.
The key players of the Global Recombinant DNA Technology Market are:
Cibus, Amgen Inc, F.Hoffmann-La Roche Ltd, GlaxoSmithKline plc., GenScript, Horizon Discovery Group plc, Merck KGaA, Novo Nordisk A/S, Pfizer Inc., New England Biolabs, Sanofi S.A and Syngene International Ltd, Biocon Limited, and others.
Global Recombinant DNA Technology Market Key Segments:
Based on product
Based on component
Based on application
Health & Disease
Based on end use
Biotechnology and Pharmaceutical Companies
Academic & Government Research Institutes
Rest of North America
Rest of Europe
Rest of Asia Pacific
Middle East & Africa
Rest of Middle East & Asia
Rest of South America
InsightSLICE adopts a research methodology which is highly meticulous and comprehensive, yielding accurate research results. Our research methodology utilizes data triangulation model which helps in the precise collection and validation of information. Our set processes for problem solving and paid primary tools guarantee that any client requirement is met with utmost diligence and accuracy. Some of the primary components that are consequential to our research approach are:
Secondary Research or Desk Research
Distinctive Data Model
Secondary Sources include but are not limited to:
Past Published Research
Historical Data and Information
Primary Sources include but are not limited to:
InsightSLICE also leverages three types of data triangulation approaches as follows:
Data Source Triangulation
Extracting data and validation from multiple type of secondary and primary sources
Combining various methodologies to validate data inputs
Applying different theories to check credibility of data sets
Major players operating in the global Recombinant DNA Technology market include Cibus, Amgen Inc, F.Hoffmann-La Roche Ltd, GlaxoSmithKline plc., GenScript, Horizon Discovery Group plc, Merck KGaA, Novo Nordisk A/S, Pfizer Inc.